Citation Impact
Citing Papers
Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)
2001 StandoutScience
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
2005 StandoutScience
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
2016
Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis
2011
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
2009 StandoutNature
Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
2013
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
2000
mTOR Signaling in Growth Control and Disease
2012 Standout
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
2006
Role of AMP-activated protein kinase in mechanism of metformin action
2001 Standout
Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: Where are the insulin resistance genes?
2008
Systems Biology Approach Reveals Genome to Phenome Correlation in Type 2 Diabetes
2013
Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data
2011
Severe iatrogenic hypoglycemia in type 2 diabetes mellitus
2006
Insulin and glucosamine infusions increase O-linked N-acetyl-glucosamine in skeletal muscle proteins in vivo
1998
Contraindications can damage your health—is metformin a case in point?
2005
Hallmarks of aging: An expanding universe
2023 Standout
Mitogen-activated protein kinase pathways
1997 Standout
Adipocytes as regulators of energy balance and glucose homeostasis
2006 StandoutNature
Oral Antihyperglycemic Therapy for Type 2 Diabetes
2002
Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony
2006
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
2007 Standout
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
2003 Standout
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
1998
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
2014 StandoutNature
Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus
2008
Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis
2017
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
1999 StandoutNature
Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction
2002
Mechanisms linking obesity to insulin resistance and type 2 diabetes
2006 StandoutNature
Type 1 diabetes
2013 Standout
Triple oral fixed‐dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study‐II)
2011
Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach
2003
Metformin
1996
THE PATHOPHYSIOLOGY AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
1997
Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus
2000
Atherosclerosis — An Inflammatory Disease
1999 Standout
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
2008
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Metformin reverses fatty liver disease in obese, leptin-deficient mice
2000
Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis
2016
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
2009
AKT/PKB Signaling: Navigating the Network
2017 Standout
TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice
1993 StandoutNobel
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
1999
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus
2004
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways
2002
Caloric restriction improves health and survival of rhesus monkeys
2017
A Stepwise Approach to Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Basal Insulin Treatment Failure
2011
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
2010
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis
2007
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
2003 Standout
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
2017
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
1996
Nutrients Suppress Phosphatidylinositol 3-Kinase/Akt Signaling via Raptor-Dependent mTOR-Mediated Insulin Receptor Substrate 1 Phosphorylation
2005
The Regulation of Cell Proliferation: Advances in the Biology and Mechanism of Action of Epidermal Growth Factor
1978
Epidermal Growth Factor (Urogastrone) in Human Fluids: Size Heterogeneity*
1979
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
2007
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
2008 Standout
Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity.
1980 StandoutNobel
Hormone receptor topology and dynamics: Morphological analysis using ferritin-labeled epidermal growth factor
1979 StandoutNobel
Inhibition of Endothelial Regeneration by Type-Beta Transforming Growth Factor from Platelets
1986 StandoutScience
Cloning of Human Mineralocorticoid Receptor Complementary DNA: Structural and Functional Kinship with the Glucocorticoid Receptor
1987 StandoutScience
Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta‐analysis
2015
Triple therapy in type 2 diabetes; a systematic review and network meta-analysis
2015
The kinetics of tyrosine phosphorylation by the purified epidermal growth factor receptor kinase of A-431 cells.
1983 StandoutNobel
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Identification of residues in the nucleotide binding site of the epidermal growth factor receptor/kinase.
1985 StandoutNobel
Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.
1980 StandoutNobel
Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus
2012
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
1997 Standout
A chemical approach for identifying O -GlcNAc-modified proteins in cells
2003 StandoutNobel
Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis
2017
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes
2005
Affinity labeling of the protein kinase associated with the epidermal growth factor receptor in membrane vesicles from A431 cells.
1982 StandoutNobel
Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta‐analysis
2013
A Systematic Review of Adherence With Medications for Diabetes
2004 Standout
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine ( L antus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)
2015
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
2011
Pharmacologic Therapy for Type 2 Diabetes Mellitus
1999
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice
2017
Mitochondrial Dysfunction and Type 2 Diabetes
2005 StandoutScience
The tumor promoter 12‐0‐tetradecanoyl‐phorbol‐13‐acetate enhances the proliferative response of Balb/c‐3T3 cells to hormonal growth factors
1979
Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
1985 StandoutScience
Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds
2001 StandoutNobel
Epidermal Growth Factor (Urogastrone) in Human Tissues*
1979
Fat Mobilization in Adipose Tissue Is Promoted by Adipose Triglyceride Lipase
2004 StandoutScience
Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets.
1983
George Lyman Duff Memorial Lecture. Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components.
1981
Epidermal Growth Factor
1979 StandoutNobel
A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles.
1982 StandoutNobel
Adjust to Target in Type 2 Diabetes
2008
One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes
2004
Triple therapy with glimepiride in patients with type 2diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study
2005
Vascular wall growth control: the role of the endothelium.
1981
Review of basal‐plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus
2017
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
2000
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
1984 StandoutNature
Characterization of the interaction of 5'-p-fluorosulfonylbenzoyl adenosine with the epidermal growth factor receptor/protein kinase in A431 cell membranes.
1983 StandoutNobel
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
2005
Protein phosphorylation in human placenta stimulation by epidermal growth factor
1980
Rapid enhancement of protein phosphorylation in A-431 cell membrane preparations by epidermal growth factor.
1979 StandoutNobel
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
2018
Mechanism by which metformin reduces glucose production in type 2 diabetes.
2000
Human epidermal growth factor precursor: cDNA sequence, expressionin vitroand gene organization
1986
Cassette of Eight Exons Shared by Genes for LDL Receptor and EGF Precursor
1985 StandoutScienceNobel
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
2002 Standout
The Pathogenesis of Atherosclerosis — An Update
1986 Standout
Role of Brain Insulin Receptor in Control of Body Weight and Reproduction
2000 StandoutScience
Hypoglycemia in Type 2 Diabetes
2005
Works of George Dailey being referenced
Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus
2001
Weight Change in Patients with Type 2 Diabetes Starting Basal Insulin Therapy: Correlates and Impact on Outcomes
2014
Metabolic Effects of Metformin in Non-Insulin-Dependent Diabetes Mellitus
1995
New strategies for basal insulin treatment in type 2 diabetes mellitus
2004
Effect on glycemic control of the addition of 2.5mg glipizide GITS to metformin in patients with T2DM
2004
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
2010
Glycemic control with Glyburide/Metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial
2004
Optimum management of type 2 diabetes – timely introduction, optimization and intensification of basal insulin
2008
Overall Mortality in Diabetes Mellitus: Where Do We Stand Today?
2011
Estimation of glucose-alanine-lactate-glutamine cycles in postabsorptive humans: role of skeletal muscle
1995
Do estrogens improve bone mineral density in osteoporotic women over age 65?
1992
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study
2011
Insulin Glulisine Provides Improved Glycemic Control in Patients With Type 2 Diabetes
2004
Triple Therapy in Type 2 Diabetes
2006
Repaglinide in Type 2 Diabetes: A 24‐Week, Fixed‐Dose Efficacy and Safety Study
2000
Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative.
1995
Reduced Hypoglycemia Risk With Insulin Glargine
2005
Homologous Radioimmunoassay for Human Epidermal Growth Factor (Urogastrone)*
1978